INNV-10. OVERCOMING CHALLENGES AND OPTIMIZING PATIENT OUTCOMES WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY

Abstract BACKGROUND Tumor Treating Fields therapy (TTFields; 200 kHz) is a noninvasive, locoregional, antimitotic treatment approved for newly diagnosed glioblastoma (ndGBM), recurrent GBM, and malignant pleural mesothelioma, being investigated in range of solid tumors. METHODS Healthcare professionals (HCPs) specializing radiation oncology, neuro-oncology, medical oncology as well patients with GBM caregivers were asked to complete online surveys between October–December 2021 July–September (patients/caregivers). RESULTS Overall, n=130 HCPs n=50 patients/caregivers responded the surveys. The majority (68%) considered TTFields + temozolomide standard care ndGBM, yet only 35% report strongly recommending it option. Barriers recommendation included need additional patient services practice support training, prescription process etc., guidance on insurance coverage (31% each), increase awareness (20%), lack testimonials (20%). HCP perceptions barriers often higher than reported by themselves; time wearing device (46% vs 35%); visibility (37% 24%), concerns shaving head 18%), carrying (34% 18%). Awareness resources provided manufacturer was relatively low (HCP: peer-peer knowledge exchange program [25%], product brochures [16%–30%]; patient: webcasts [15%], website [23%], educational videos [25%–26%], [26%–27%], buddy [29%], dedicated service information [32%]), despite desire support. CONCLUSION Increasing existing programs continues be critical overcoming initiation optimize outcomes.